Press Release Nov 16 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release regarding a legal update on its marketing partner's appeal in the US. The Appeals Court has rejected Alvogen's appeal concerning Ibrutinib Tablets, which are proposed generic equivalents to Imbruvica® Tablets. NATCO and Alvogen are currently evaluating their options moving forward after this decision.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release Nov 12 2022
- Press Release Nov 09 2022
- Press Release Oct 21 2022
- Press Release Oct 04 2022
- Press Release Sep 24 2022
Later from NATCO Pharma
- Press Release Dec 05 2022
- Press Release Feb 04 2023
- Natco Pharma Limited Press Release Feb 13 2023
- Natco Pharma Limited Press Release Mar 01 2023
- Natco Pharma Limited Press Release Mar 10 2023
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma